A Phase II Clinical Trial to Assess the Effect of HC-SVT-1001 (Autologous Fat Stem Adult Mesenchymal Cells Expanded and Combined With a Tricalcium Phosphate Biomaterial) and HC-SVT-1002 (Allogeneic Fat Stem Adult Mesenchymal Cells Expanded and Combined With a Tricalcium Phosphate Biomaterial) in the Surgical Treatment of Atrophic Pseudarthrosis of Long Bones
Latest Information Update: 01 Nov 2021
At a glance
- Drugs HC SVT-1001 (Primary)
- Indications Pseudoarthrosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms Bonecure
- Sponsors SALVAT
- 16 Mar 2021 Status changed from active, no longer recruiting to completed.
- 20 Oct 2020 Planned End Date changed from 1 Jun 2021 to 1 Oct 2021.
- 20 Oct 2020 Status changed from recruiting to active, no longer recruiting.